| Bioactivity | Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC)[1][2][3]. |
| Invitro | Cobolimab (0.0001-10 nM；3 d) 在预激活 T 细胞中以剂量依赖性方式促进 TIM-3 内化，IC50 值为 0.4464 nM[3]。Cobolimab (20 µg/mL；24 h) 通过抑制 TIM-3 显著增加了 CD8+ T 细胞含量[4]。 |
| Name | Cobolimab |
| CAS | 2022215-65-0 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Falchook G S, et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)[J]. 2022. [2]. Markham A. Dostarlimab: First Approval. Drugs. 2021 Jul;81(10):1213-1219. [3]. Kuang Z, et al. A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy. Antib Ther. 2020 Nov 9;3(4):227-236. [4]. Sun CY, et al. T cell exhaustion drives osteosarcoma pathogenesis. Ann Transl Med. 2021 Sep;9(18):1447. |